Cancer Genetics, Inc. (Nasdaq: CGIX) announced the successful CLIA validation and approval of its next generation sequencing (NGS) assay that ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE